The crosslinking study that Drs. Holzman and Solomon have been involved in has been exploring treatment for KCN patients that have actually had loss in their BCVA prior to enrollment.  This is an explicit study inclusion criteria.  However, like Dr. Tullo mentions here, once this procedure is FINALLY ... ugh ... waiting forever here ... approved, then we can feel safe in recommending it as a treatment modality for our patients that definitely have KCN and are at risk for losing BCVA due to the progressive disease.  - jw